Armstrong Advisory Group’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$50.6K Hold
263
– – ﹤0.01% 429
2026
Q2
$18.4K Hold
263
– – ﹤0.01% 607
2026
Q1
$13.4K Hold
263
– – ﹤0.01% 636
2025
Q4
$7.76K Hold
263
– – ﹤0.01% 718
2025
Q3
$6.79K Hold
263
– – ﹤0.01% 735
2025
Q2
$7.26K Hold
263
– – ﹤0.01% 713
2025
Q1
$10.9K Hold
263
– – ﹤0.01% 605
2024
Q4
$10.9K Sell
263
-100
-28% -$4.78K ﹤0.01% 605
2024
Q3
$24.3K Buy
363
+100
+38% +$9.18K ﹤0.01% 473
2024
Q2
$31.2K Buy
263
+51
+24% +$6.45K ﹤0.01% 420
2024
Q1
$21.1K Hold
212
– – ﹤0.01% 473
2023
Q4
$21.1K Hold
212
– – ﹤0.01% 473
2023
Q3
$21.9K Hold
212
– – ﹤0.01% 470
2023
Q2
$25.8K Hold
212
– – ﹤0.01% 444
2023
Q1
$32.6K Hold
212
– – ﹤0.01% 396
2022
Q4
$38.1K Buy
+212
New +$34.7K 0.01% 371

Other funds holding MRNA

Armstrong Advisory Group's MRNA Position: Q3 2026 in Review

Armstrong Advisory Group held its Moderna (MRNA) position steady in Q3 2026 at 263 shares worth $50.6K. The position accounts for ﹤0.01% of the portfolio, ranked #429.

Armstrong Advisory Group first reported a position in MRNA in Q4 2022 and has held it in 16 quarters since. 962 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Armstrong Advisory Group held 263 shares of Moderna worth $50.6K as of Q3 2026.
  • Armstrong Advisory Group left its Moderna share count unchanged in Q3 2026.
  • Moderna made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q3 2026, its #429 holding.
  • Armstrong Advisory Group first reported a position in Moderna in Q4 2022 and has held it in 16 quarters since.
  • 962 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Armstrong Advisory Group's 13F filing for Q3 2026, filed 9 Oct 2026.